Objectives. Twice-daily dosing of proton pump inhibitor (PPI), the standard therapy for gastro-oesophageal reflux disease (GERD), is an effective therapy for GERD in SSc. The aim of this study was to compare the efficacy of omeprazole in combination with domperidone vs in combination with algycon in reducing the severity and frequency of reflux symptoms of PPI partial response (PPI-PR) GERD in SSc.
Introduction
SSc is a rare systemic disease causing excessive skin and internal organ fibrosis. SSc is classified into two major subsets, lcSSc and dcSSc [1] . LcSSc is characterized by skin tightness of the face, hands, feet, forearms and legs, while dcSSc is characterized by skin tightness of the trunk and both extremities. DcSSc is associated with internal organ fibrosis and its prognosis is worse than lcSSc [2] .
Involvement of the gastrointestinal tract in SSc leads to high morbidity [3] , the prevalence of which is between 54 and 90% [3, 4] . Oesophageal involvement is the most frequently found in SSc (range 3096%) [47] . Gastro-oesophageal reflux disease (GERD) is a manifestation of oesophageal involvement in both SSc subsets. Dysphagia, heartburn and regurgitation are typical oesophageal symptoms of GERD. Chronic laryngitis, laryngospasm, recurrent pneumonia and chronic cough are extra-oesophageal manifestations of GERD [5, 8, 9] . Interstitial lung disease is associated with GERD in SSc [10] . Notwithstanding these known associations, the actual pathophysiology of GERD in SSc is not well understood. Hypotony of the lower oesophageal sphincter caused by excessive deposition of collagen in the lamina propria and the muscularis mucosae may contribute to GERD development in SSc [3] . Recent data reveal no association between the extent of oesophagus damage and the intensity of symptoms, duration of disease or subset of SSc [11] .
In general, no test is required for the diagnosis of GERD when typical manifestations for GERD are present and the patient responds to therapy [12, 13] . Endoscopy can be helpful for confirming oesophagitis-associated GERD or when therapy fails [14] . In addition, physiological tests, such as 24 h pH monitoring, can help demonstrate abnormal acid exposure of the oesophagus in the absence of oesophageal lesions with typical reflux symptoms [14, 15] . Otherwise, CT and MRI are invasive procedures that may be helpful for defining oesophageal involvement in SSc but not for the diagnosis of oesophageal involvement or GERD [16] .
The GERD Questionnaire (GERD-Q) is a non-invasive screening tool that has a high sensitivity for diagnosis of GERD in SSc. A recent study on the GERD-Q revealed that a score of 54 vs 58 provided a respective sensitivity and specificity of 96.9 and 50% vs 65 and 100% for diagnosis GERD in SSc [17] . GERD-Q could therefore be a useful tool for diagnosing GERD in SSc when endoscopy cannot be performed due to limitations in opening the mouth and/or 24 h pH monitoring is unavailable.
Lifestyle modification should be advised as a nonpharmacological therapy for all patients with GERD, and proton pump inhibitor (PPI) twice-daily dosing, a standard-dose therapy for GERD, is an effective pharmacotherapy for uncomplicated GERD in SSc [15, 18] . The evidence shows that there is no difference in response between 4 and 8 weeks of full-dose PPI administration [15] . There are, however, no data on the response rate of standard-dose PPI or the prevalence of a PPI partial response (PR) in SSc with GERD.
According to the pathophysiology, motility problems are the mechanism underlying development of GERD in SSc leading to reflux. Prokinetic agents could be helpful for relief GERD symptoms by facilitating oesophageal motility and increasing lower oesophageal sphincter pressure [19] . Even though various agents are used for the treatment of gastrointestinal involvement in SSc, there have been no randomized controlled trials to support their use. Experts suggest using a prokinetic agent for the treatment of GERD and its symptoms [20, 21] . Domperidone is a commonly used prokinetic agent used in combination with PPI for GERD therapy in daily practice-it is a potent peripheral dopamine antagonist and the common dosage is 10 mg three times daily before meals. In our practice, PPI is used in combination with domperidone for refractory GERD in SSc, and this regimen seems to be more effective than PPI alone.
The combination of alginic acid and a mixture of antacids (CAA) are reported to be an effective therapy for GERD by relieving the reflux symptoms. The mechanisms of action include neutralizing the acid in the oesophagus and diminishing reflux [22] , but there is no effect on lower oesophageal sphincter pressure [23] . Although CAA is effective for relief of reflux symptoms, there are only a few reports of CAA treatment in GERD [24, 25] . Lai et al. [24] found that alginic acid was more effective than antacid for relief of heartburn, regurgitation, vomiting and belching in non-oesophagitis GERD at 3 and 6 weeks of treatment. A study by the Cooperative Oesophageal Group found that the combination of cimetidine with alginic acid was superior to full-dose cimetidine alone (400 mg four times daily) for improvement of reflux symptoms after the 12th week of treatment [25] .
There is evidence for greater efficacy with the combination of acid suppression [histamine 2 receptor antagonist (H2RA)] plus CAA vs acid suppression alone. The efficacy of the combination of PPI with CAA or domperidone (which has a different mechanism of action on GERD) has not recently been investigated in SSc. We therefore set out to investigate the efficacy of PPI and CAA compared with PPI and domperidone in PPI-PR GERD in SSc.
Our primary objective was to compare the efficacy of omeprazole with domperidone vs omeprazole with algycon in omeprazole PR GERD in SSc vis-à -vis the severity of heartburn and regurgitation by visual analogue score (VAS), frequency of symptoms [by the frequency scale for symptoms of gastro-oesophageal reflux disease (FSSG)] and quality of life (QoL) [by EuroQol five-dimensions questionnaire (EQ-5D) score]. The secondary objective was to evaluate the change in SScrelated PPI-PR GERD vis-à -vis the severity of heartburn and regurgitation (by VAS), frequency of symptoms (by FSSG) and QoL (by EQ-5D score) after 4 weeks of treatment.
Methods
The study protocol included 4 weeks of randomized parallel study. The study was conducted between May 2013 and August 2015.
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The study population
Inclusion criteria
We included SSc patients between 18 and 65 years of age, diagnosed with GERD with a GERD-Q score 58 and defined as PPI-PR and not receiving any prokinetic drug or algycon within 2 weeks before baseline evaluation.
Exclusion criteria
We excluded those who were pregnant or lactating, with a previous history of gastro-oesophageal surgery or undergoing endoscopic therapy (due to severe erosive oesophagitis), presenting with Barrett's oesophagus, bedridden and unable to care for themselves, with active malignant disease, presenting with uncontrolled or severe medical problems (i.e. asthma, angina, cardiac hepatic or renal diseases), presenting with active infection needing systemic antibiotic or non-absorbable antibiotic, a history of allergies or food sensitivities, using domperidone or algycon, receiving prohibited co-medications that may interact with or attenuate GERD symptoms (i.e. tetracycline, ferrous salt, digoxin, isoniacid, oral bisphosphonate), having difficulty chewing or a diagnosis of celiac disease.
All of the enrolled patients had the head of their bed elevated at least 30 , had an interval between last meal and bedtime of at least 2 h, usually had small meals and did not have diets that could provoke GERD symptoms (i.e. spicy diet, caffeine and carbonated drinks).
The intervention
SSc patients having PPI-PR were randomly assigned to either treatment group by blocks of eight in a 1:1 ratio. The subjects received 20 mg omeprazole twice daily plus 10 mg domperidone thrice daily and algycon placebo (1 chewing tablet thrice daily) or algycon (1 chewing tablet thrice daily) and domperidone placebo (1 tablet thrice daily). The treatment was continued for 4 weeks. The attending physician could adjust all medical treatment for their underlying SSc and concomitant medications apart from any prohibited medication.
The study endpoint was assessed at week 4 (after treatment). The primary endpoint was a comparison of efficacy between omeprazole in combination with domperidone vs omeprazole in combination with algycon on the severity of heartburn and regurgitation, frequency of symptoms and QoL. The secondary endpoint was changes in these parameters after 4 weeks of treatment.
Any patient could be withdrawn from the study in case of active upper gastrointestinal bleeding, need for hospitalization or i.v. PPI. An adverse drug reaction or event was recorded if the patient developed a new onset of symptoms that could be related to the treatment medication or could not be explained by the SSc disease itself.
Operational definitions
A diagnosis of SSc was based on the ACR criteria [26] . SSc was classified as the limited or diffuse type as per the classification of LeRoy et al. [1] . GERD was defined when the patient complained of heartburn and/or regurgitation and had a GERD-Q score 58 [17] .
Heartburn was defined by a burning sensation or discomfort behind the sternum extending to the neck (worse after meals or on reclining) that improved with antacids [27] . Regurgitation was the perception of flow of refluxed gastric contents into the mouth or hypopharynx [27] .
The definition of omeprazole PR GERD was fulfilled when the reflux symptoms (evaluated by FSSG) or VAS (severity of symptoms) improved <50% after omeprazole 20 mg twice daily for 4 weeks compared with baseline. The definition of a non-response to treatment was fulfilled when the reflux symptoms (evaluated by FSSG) or VAS (severity of symptoms) improved <50% after the combination treatment for 4 weeks compared with baseline.
Drug information
Omeprazole (Miracid; Berlin Pharmaceutical, Bangkok) is a PPI in a delayed-release capsule containing 20 mg/capsule. It blocks the final step in gastric acid secretion by specific inhibition of H + /K + ATPase enzyme (proton pump). The drug prolongs elimination of diazepam, warfarin and phenytoin and side effects, though rare, include headache, skin rash, back pain, dizziness and gastrointestinal disturbance (abdominal pain, nausea, diarrhoea, flatulence). The prescription is contraindicated in those who have any history of hypersensitivity to benzimidazoles. Domperidone (Molax-M; Siam Pharmaceutical, Bangkok) is a prokinetic that blocks the peripheral dopamine receptor. One tablet contains 10 mg of domperidone. It is rapidly absorbed but delayed by food. The adverse drug reactions include transient intestinal cramps, gynaecomastia and galactorrhoea. A serious but uncommon side effect is cardiac arrhythmia, particularly at high doses and among elderly patients. The prescription should be cautioned in pregnancy and anticholinergic agents may inhibit the anti-dyspeptic effects.
Algycon is a CAA drug. One tablet contains 200 mg alginic acid, 30 mg aluminium hydroxide gel and 40 mg magnesium carbonate. Algycon is a chewable tablet and has a rapid onset of action; the duration of action is 4 h. Aluminium hydroxide 3 g and magnesium carbonate 2 g are the maximum dose of algycon. The common side effects are hiccough, diarrhoea and constipation. No serious adverse reactions have been reported. The drug decreases the absorption of tetracycline, ferrous salt, digoxin and isoniacid. The prescription is contraindicated during pregnancy and lactation and for those under sodium restrictions (as the medicine contains 9.2 mg sodium per tablet) [28] . It is a product of Tai Yu Chemical & Pharmaceutical, Taiwan, ROC and is distributed in Thailand by American Taiwan Biopharm, Bangkok.
Sample size
The sample size was calculated as per recent literature [24] in which the mean for the treatment and control group was 6.39 (S.D. 2.32) and 4.44 (S.D. 2.50), respectively. In order to detect a difference at 90% power at a significance level of 0.05, the sample size for each group should be n = 33 (overall n = 66). To compensate for dropouts (10%), we recruited 80 patients (40 patients in each group).
Statistical analysis
Baseline patient characteristics were summarized using descriptive statistics (percentages, means and S.D.s). Analyses included Student's unpaired t-test, the MannWhitney U test, the chi-square test and Fisher's exact test, performed as appropriate. The difference between the two means of VAS and FSSG between groups was assessed using the unpaired Student's t-test for the parametric data and the MannWhitney U test for the nonparametric data. Differences between the two means of VAS and FSSG before and after treatment were assessed using the paired Student's t-test. All P-values were twotailed and the statistical significance was set at P < 0.05. All statistics were analysed using STATA version 11.2 (StataCorp, College Station, TX, USA).
The Human Research Ethics Committee of Khon Kaen University approved the study as per the Helsinki Declaration and the Good Clinical Practice Guidelines (HE561044). All eligible patients signed informed consent before enrolment. The sponsor had no role in the study. The trial registration number is NCT01878526.
Results

Patients
A total of 151 SSc patients with GERD were enrolled in the study and 3 were lost to follow-up before assessment of their PPI response; 148 patients were included in the analysis. The majority was female [97 (65.5%)] having the dcSSc subset [102 (68.9%)]. The respective mean age at SSc onset, age at GERD onset and duration of disease were 48.9, 53.0 and 2.1 years, respectively. The overall clinical data of SSc patients with GERD are presented in Table 1 .
Eighty-eight patients presented with PPI-PR GERD, for a prevalence of 59.4% (95% CI 51.1, 67.4), and most of these were female [55 (62.5%)]. Eighty cases were randomized to either domperidone or algycon therapy. There were two cases lost to follow-up (one in each group). In the domperidone group, one patient stopped the medication after taking it for 2 days, because of fatigue. In the algycon group, one patient died due to dilated cardiomyopathy and one patient was contaminated by domperidone treatment. The remaining 75 cases were included in the analysis (38 in the domperidone group and 37 in the algycon group) (Fig. 1) . The baseline patient data for both the domperidone and algycon groups are presented in Table 1 .
Efficacy
The primary endpoint, a comparison of the efficacy of omeprazole in combination with domperidone vs omeprazole in combination with algycon on the severity of reflux symptoms and frequency of symptoms in omeprazole PR GERD in SSc, are presented in Table 2 . The results revealed that the severity, frequency of the symptoms and QoL after treatment in the domperidone and algycon groups were not significantly different. Five (13.2%) and 8 patients (21.6%) in the domperidone and algycon groups, respectively, did not respond to the treatment.
The secondary endpoint, the changing severity of heartburn and regurgitation (VAS), frequency of symptoms (FSSG) and QoL (EQ-5D score) of SSc-related PPI-PR GERD, compared with week 4 are presented in Table 3 . The FSSG (both the reflux and dysmotility scores), severity (assessed by VAS) and EQ-5D VAS were significantly improved in both groups. Only the severity of night cough (assessed by VAS) was not significantly changed from baseline.
Safety
An adverse drug reaction was observed in four patients (two in each group). Nausea was seen in one patient in the domperidone group and was related to the algycon placebo therapy. Infected calcinosis cutis was reported in the domperidone group (one patient) infected digital ulcer (one patient) and leg pain (one patient) in the algycon group. Both of the patients with infections were given oral antibiotics for 2 weeks and the adverse events were resolved within 14 days. One patient in the algycon group died (15 days after randomization) due to congestive heart failure, but no autopsy was performed since the patient had been previously diagnosed with dilated cardiomyopathy.
Discussion
The prevalence of PPI-PR GERD is common. Although the twice-daily dose regimen of omeprazole is effective for therapy, almost 60% of our SSc patients were PPI-PR GERD. According to the pathogenesis of SSc, GERD is not only related to acid reflux but also oesophageal dysmotility, a common problem in SSc, so achieving only acid suppression is not enough to control GERD symptoms in the majority of patients. Since we chose omeprazole as our study drug, we could not provide the response rate for GERD therapy in SSc with other PPIs, such as pantoprazole, lansoprazole and esomeprazole, which are also effective for GERD therapy [15] .
In the general population, PPI-PR is reported in both erosive oesophagitis and non-erosive oesophagitis GERD. The data reveal that being female and underweight and having an oesophageal hiatal hernia, Helicobacter pylori infection, smoking habit or non-acid reflux were more likely to be associated with PPI-PR, particularly in non-erosive GERD [2931] .
There are no recent reports of factors associated with PPI-PR in SSc patients or whether early combination therapy of PPI and domperidone or algycon might alleviate GERD symptoms in SSc patients. We plan further research to define the predictors of PPI-PR in SSc patients.
Adding prokinetics or CAA usually increases the rate of response for GERD therapy in SSc. Our results revealed that patients who did not respond to PPI (standard for GERD therapy) responded to either prokinetic or CAA, www.rheumatology.oxfordjournals.org www.rheumatology.oxfordjournals.org even though the response between the two was not statistically different. Our study demonstrated the effectiveness of PPI with domperidone or algycon for decreasing the severity and frequency of symptoms and improving QoL in SSc. Notwithstanding, the use of prokinetics or CAA made no significant difference in treating GERD symptoms even though, according to the mechanism of action, domperidone should relieve the symptoms of GERD and algycon should relieve the symptoms of both reflux and dysmotility despite the lack of any prokinetic action. CAA is a chewable tablet and has rapid onset like antacid. After chewing, viscous foam forms in the stomach that floats over the liquid surface; the foam is a suspension of the antacid. The viscous foam acts as a barrier that decreases the amount of reflux [23] . According to the mechanism of action, it neutralizes the acid and diminishes the quantity of reflux without any effect on lower oesophageal sphincter pressure. It is possible that algycon in combination with PPI neutralizes the acid by a synergistic effect, so acid suppression might protect the oesophagus much more from acid reflux. Algycon in combination with PPI is useful for the patient who has PPI-PR to the standard dose and an unsatisfactory prokinetic side effect (i.e. galactorrhoea).
There were no serious adverse events in either the PPI with domperidone or PPI with algycon group. There was evidence that domperidone in high doses, i.e. >30 mg/ day, could be a leading cause of serious cardiac arrhythmia [32, 33] . None of our patients had serious or symptomatic cardiac arrhythmia, so domperidone at a dose of 30 mg/day could be safe in SSc with GERD patients who do not have a previous history of uncontrolled cardiac disease. However, electrocardiography should be monitored at baseline and be repeated in case of symptomatic cardiac arrhythmia or in high-risk patients (i.e. elderly persons, previous history of cardiac disease, renal or liver disease) [33] . Although the combination of PPI with either domperidone or algycon is effective for controlling GERD symptoms, 17% of our patients did not respond to the treatment. Gastric dysfunction has been postulated as the reason that it might increase the severity of GERD in SSc patients [7] . Nearly half (6 of 13) of our patients who were non-responsive to the combination of PPI with either domperidone or algycon also had stomach symptoms. It is possible that stomach dysfunction might cause a poor response for GERD therapy; however, the association was not statistically significant, perhaps because of the small number of patients who were non-responsive to the treatment. Therefore we cannot draw any conclusions about the association.
The treatment option for the patient who did not respond to the combination therapy (viz., PPI with domperidone or algycon) should be further investigated. Initially we suggest performing oesophagogastroduodenoscopy for exclusion of H. pylori infection and performing jejunal aspiration for exclusion of small bowel bacterial overgrowth, which might be related to GERD in SSc [34] . Endoscopy is, however, an invasive tool for GERD diagnosis in SSc patients due to potential complications, so there are some limitations (i.e. difficulty undergoing endoscopy for those who have limited mouth opening or desaturation from interstitial lung fibrosis). In our daily practice, endoscopy is not routinely performed in all SSc patients with GERD, but it is used for patients who do not respond to the initial treatment. In case there is no H. pylori infection according to the endoscopy, treatment options might include anti-anxiety medications [35, 36] , given in combination with PPI (omeprazole 40 mg/day) and H2RA (ranitidine 300 mg/day), particularly for treatment of nocturnal reflux symptoms [37] , or a combination of PPI, prokinetics and algycon.
Our study has some limitations. First, we did not do endoscopy or 24 h pH monitoring for the diagnosis of GERD, because the procedures are invasive, so we applied the silver standard, GERD-Q, which has proven to have high specificity for the diagnosis of GERD in SSc [17] . Since we used a silver standard, we cannot define the response rate in the patients with erosive and nonerosive oesophagitis. Second, the number of the patients who did not respond to the combination treatment was too low to investigate the predictors associated with a poor response. Third, we did not investigate H. pylori infection and small bowel bacterial overgrowth in those with PPI-PR, as mentioned, as well as the uncertain association between H. pylori and GERD [38] . Therefore we cannot conclude whether H. pylori and/or small bowel bacterial overgrowth influences PPI-PR among our SSc with GERD patients. Fourth, we asked about the patients' lifestyle before and at the end of the study, but we cannot declare that all of our patients complied with our lifestyle suggestions during the study. Finally, we did not do electrocardiogram screening before or during domperidone treatment, so we cannot define the prevalence of silent cardiac arrhythmia among the patients.
The strengths of this study include that it is the first study on the prevalence of PPI-PR with standard-dose therapy in SSc with GERD. It is also the first randomized placebo-controlled trial of PPI-PR with standard-dose therapy in SSc with GERD and QoL was a primary outcome. Finally, the data demonstrate the feasibility of GERD treatment in SSc. Our study is fundamental for better care and improved the QoL of SSc patients.
Conclusion
The prevalence of PPI-PR GERD is not uncommon. Domperidone and algycon are equally effective treatments when used in combination with omeprazole. Notwithstanding, 17% of patients were non-responsive, so the effectiveness of domperidone, algycon and PPI combination therapy should be further investigated.
